摘要
目的:观察不同类型冠心病(CHD)患者外周血清基质金属蛋白酶9(MMP9)、白细胞分化抗原配体40(sCD40L)水平变化及其相关性。方法采用酶联免疫吸附法测定90例不同类型CHD患者[其中急性心肌梗死30例(AMI组),不稳定型心绞痛31例(UAP组),稳定型心绞痛29例(SAP组)]与对照组25例血清中MMP9、sCD40L 的水平。结果 AMI 组和 UAP 组血清 MMP9水平显著高于 SAP 组[(69.48±4.76)ng/mL、(66.61±5.30)ng/mL,(30.44±7.66)ng/mL,t=1.425、0.075,均P<0.05],AMI组与UAP组血清MMP9、sCD40L水平差异无统计学意义(P>0.05);SAP组与正常对照组差异无统计学意义(P>0.05);AMI组及UAP组血清MMP9、sCD40L水平呈正相关(分别为r=0.96,P<0.01;r=0.97,均P<0.01)。结论急性冠脉综合征患者血清MMP9、sCD40L水平明显升高,可作为ASA患者病情评估及预测斑块不稳定性的一个重要指标。
Objective To observe serum sCD40L,MMP9 levels and their relevance with different types of coronary heart disease(CHD).Methods The present study was involved in 90 patients with CHD,including acute myocardial infarction(AMI)30 case,unstable angina pectoris(UAP)31 case,stable angina pectoris (SAP)29 case and another 25 normal controls.The serum MMP9 and sCD40L levels were detected with enzyme-linked immunosor-bent assay.Results The levels of MMP9,sCD40L in AMI and UAP group were significantly higher than those in SAP group[(69.48 ±4.76)ng/mL,(66.61 ±5.30)ng/mL,(30.44 ±7.66)ng/mL,t=1.425,0.075,all P〈0.05], there were no statistically significant differences in the serum MMP9,sCD40L levels between AMI group with UAP group (all P〉0.05 ),and also there were no ststitically signiticant differeces in the serum MMP9,sCD40L levels between SAP group with control group (all P〉0.05).MMP9 level in AMI and UAP group was positively related with sCD40L (r=0.96,P〈0.01 and r=0.97,P〈0.01 ).Conclusion The serum sCD40L and MMP9 levels of acute coronary syndrome(ACS)increase significantly,and can be used as an important index to assess the severity of CAD and predict the instability of plaque in CAD patients.
出处
《中国基层医药》
CAS
2017年第2期178-180,共3页
Chinese Journal of Primary Medicine and Pharmacy
基金
河南省科技攻关项目(132102310222)